Advertisement

Morbus Hodgkin

  • Ralf Küppers
  • Klaus Rajewsky
  • Andrea Staratschek-Jox
  • Jürgen Wolf
  • Volker Diehl
Part of the Molekulare Medizin book series (MOLMED)

Zusammenfassung

Der Morbus Hodgkin (MH) ist eine maligne Erkrankung des lymphatischen Systems, die heute in der Mehrzahl der Fälle kurativ behandelt werden kann. Mehr als 150 Jahre nach ihrer Erstbeschreibung durch Thomas Hodgkin ist jedoch immer noch weitgehend unverstanden, welche Faktoren zur Entstehung des Lymphoms, das in besonderer Weise die Merkmale einer Neoplasie mit den Zeichen einer Infektionskrankheit vereinigt, beitragen. Im Folgenden werden daher klinische und molekulargenetische Aspekte der Lymphompathogenese dargestellt und ein Überblick über derzeitige Therapiekonzepte gegeben.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Armitage JO (1995) Treatment strategies for patients with relapsed or refractory Hodgkin’s disease. Ann Oncol 6:517–518PubMedGoogle Scholar
  2. Bargou RC, Emmerich F, Krappmann D et al. (1997) Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J Clin Invest 100:2961–2969PubMedCrossRefGoogle Scholar
  3. Baumforth KRN, Young LS, Flavell KJ, Constandinou C, Murray PG (1999) The Epstein-Barr virus and its association with human cancers. J Clin Pathol Mol Pathol 52:307–322CrossRefGoogle Scholar
  4. Bhatia S, Robison LL, Oberlin O et al. (1996) Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 334:745–751PubMedCrossRefGoogle Scholar
  5. Bierman PJ, Vose JM, Armitage JO (1994) Autologous transplantation for Hodgkin’s disease: coming of age? Blood 83:1161–1164PubMedGoogle Scholar
  6. Bjorkholm M, Holm G, De Faire U, Mellsted H (1977) Immunological defects in healthy twin siblings to patients with Hodgkin’s disease. Scand J Haematol 19:396–404PubMedCrossRefGoogle Scholar
  7. Bjorkholm M, Holm G, Mellstedt H (1978) Immunological family studies in Hodgkin’s disease. Is the immunodeficiency horizontally transmitted? Scand J Haematol 20:297–305PubMedCrossRefGoogle Scholar
  8. Bonnadonna G, Valagussa P, Sanorano A (1986) Alternating non-cross-resistant combination of MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med 104:739–746Google Scholar
  9. Braeuninger A, Küppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML (1997) Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci USA 94:9337–9342PubMedCrossRefGoogle Scholar
  10. Bräuninger A, Hansmann ML, Strickler JG et al. (1999) Identification of common germinal-center B-cell precursors in two patients with both Hodgkin’s disease and Non-Hodgkin’s lymphoma. N Engl J Med 340:1239–1247PubMedCrossRefGoogle Scholar
  11. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT (1999) Mutations in the IκBα gene in Hodgkin’s disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 18:3063–3070PubMedCrossRefGoogle Scholar
  12. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R (1998) Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405–411PubMedCrossRefGoogle Scholar
  13. Canellos GP, Propert K, Cooper R (1988) MOPP vs. ABVD vs. MOPP alternating with ABVD in advanced Hodgkin’s disease: a prospective randomized CALGB trial. Proc Am Soc Clin Oncol 7:230–238Google Scholar
  14. Canellos GP, Anderson JR, Propert KJ et al. (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478–1484PubMedCrossRefGoogle Scholar
  15. Carbone A, Gloghini A, Gruss HJ, Pinto A (1995) CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin’s disease. Am J Pathol 147:912–922PubMedGoogle Scholar
  16. Carde P, Hagenbeek A, Hayat M et al. (1993) Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin’s disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11:2258–2272PubMedGoogle Scholar
  17. Chen WG, Chen YY, Kamel OW, Koo CH, Weiss LM (1996) p53 mutations in Hodgkin’s disease. Lab Invest 75:519–527PubMedGoogle Scholar
  18. Correa P, O’Conor GT (1971) Epidemiologic patterns of Hodgkin’s disease. Int J Cancer 8:192–201PubMedCrossRefGoogle Scholar
  19. Cossman J, Annunziata CM, Barash S et al. (1999) Reed-Sternberg cell genome expression supports a B-cell lineage. Blood 94:411–416PubMedGoogle Scholar
  20. Delabie J, Tierens A, Wu G, Weisenburger DD, Chan WC (1994) Lymphocyte predominance Hodgkin’s disease: lineage and clonality determination using a single-cell assay. Blood 84:3291–3298PubMedGoogle Scholar
  21. Delabie J, Tierens A, Gavriil T, Wu G, Weisenburger DD, Chan WC (1996) Phenotype, genotype and clonality of Reed-Sternberg cells in nodular sclerosis Hodgkin’s disease: results of a single-cell study. Br J Haematol 94:198–205PubMedCrossRefGoogle Scholar
  22. Drexler HG, Dirks WG, MacLeod RA (1999) False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 13:1601–1607PubMedCrossRefGoogle Scholar
  23. Emmerich F, Meiser M, Hummel M et al. (1999) Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 94:3129–3134PubMedGoogle Scholar
  24. Engert A, Diehl V, Schnell R et al. (1997) A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin’s lymphoma. Blood 89:403–410PubMedGoogle Scholar
  25. Ford RJ, Tsao J, Kouttab NM, Sahasrabuddhe CG, Mehta SR (1984) Association of an interleukin abnormality with the T cell defect in Hodgkin’s disease. Blood 64:386–392PubMedGoogle Scholar
  26. Fuks Z, Strober S, Bobrove AM, Sasazuki T, McMichael A, Kaplan HS (1976) Long term effects of radiation of T and B lymphocytes in peripheral blood of patients with Hodgkin’s disease. J Clin Invest 58:803–814PubMedCrossRefGoogle Scholar
  27. Goossens T, Klein U, Küppers R (1998) Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. Proc Natl Acad Sci USA 95:2463–2468PubMedCrossRefGoogle Scholar
  28. Gravel S, Delsol G, Al Saati T (1998) Single-cell analysis of the t(14;18)(q32;p21) chromosomal translocation in Hodgkin’s disease demonstrates the absence of this transformation in neoplastic Hodgkin and Reed-Sternberg cells. Blood 91:2866–2874PubMedGoogle Scholar
  29. Grufferman S, Delzell E (1984) Epidemiology of Hodgkin’s disease. Epidemiol Rev 6:76–106PubMedGoogle Scholar
  30. Gupta RK, Patel K, Bodmer WF, Bodmer JG (1993) Mutation of p53 in primary biopsy material and cell lines from Hodgkin disease. Proc Natl Acad Sci USA 90:2817–2821PubMedCrossRefGoogle Scholar
  31. Gutensohn N, Cole P (1980) Epidemiology of Hodgkin’s disease. Semin Oncol 7:92–102PubMedGoogle Scholar
  32. Hancock SL, Tucker MA, Hoppe RT (1993) Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 85:25–31PubMedCrossRefGoogle Scholar
  33. Hansmann M-L, Weiss LM, Stein H, Harris NL, Jaffe ES (1999) Pathology of lymphocyte predominance Hodgkin’s disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM (eds) Hodgkin’s disease. Lippencott Williams & Wilkins, Philadelphia, pp 169–180Google Scholar
  34. Harris NL, Jaffe ES, Stein H et al. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361–1392PubMedGoogle Scholar
  35. Hartmann F, Renner C, Jung W, Sahin U, Pfreundschuh M (1996) Treatment of Hodgkin’s disease with bispecific antibodies. Ann Oncol 4:143–146Google Scholar
  36. Hasse U, Tinguely M, Leibundgut EO et al. (1999) Clonal loss of heterozygosity in microdissected Hodgkin and Reed-Sternberg cells. J Natl Cancer Inst 91:1581–1583PubMedCrossRefGoogle Scholar
  37. Henry-Amar M (1992) Second cancer after the treatment for Hodgkin’s disease: a report from the International Database on Hodgkin’s Disease. Ann Oncol 4:117–128Google Scholar
  38. Hersh EM, Oppenheim JJ (1965) Impaired in vivo lymphocyte transformation in Hodgkin’s disease. N Engl J Med 273:106–112CrossRefGoogle Scholar
  39. Hodgkin T (1832) On some morbid appearances of the absorbent glands and spleen. Med Chir Trans 17:68–114PubMedGoogle Scholar
  40. Hoppe RT (1990) Radiation therapy in the management of Hodgkin’s disease. Semin Oncol 17:704–715PubMedGoogle Scholar
  41. Hummel M, Ziemann K, Lammert H, Pileri S, Sabattini E, Stein H (1995) Hodgkin’s disease with monoclonal and polyclonal populations of Reed-Sternberg cells. N Engl J Med 333:901–906PubMedCrossRefGoogle Scholar
  42. Inghirami G, Macri L, Rosati S, Zhu BY, Yee HT, Knowles DM (1994) The Reed-Sternberg cells of Hodgkin disease are clonal. Proc Natl Acad Sci USA 91:9842–9846PubMedCrossRefGoogle Scholar
  43. Irsch J, Nitsch S, Hansmann ML et al. (1998) Isolation of viable Hodgkin and Reed-Sternberg cells from Hodgkin disease tissues. Proc Natl Acad Sci USA 95:10117–10122PubMedCrossRefGoogle Scholar
  44. Jansen MP, Hopman AH, Bot FJ et al. (1999) Morphologically normal, CD30-negative B-lymphocytes with chromosome aberrations in classical Hodgkin’s disease: the progenitor cell of the malignant clone? J Pathol 189:527–532PubMedCrossRefGoogle Scholar
  45. Joos S, Küpper M, Ohl S et al. (2000) Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60:549–552PubMedGoogle Scholar
  46. Jox A, Zander T, Kornacker M et al. (1998) Detection of identical Hodgkin-Reed Sternberg cell specific immunoglobulin gene rearrangements in a patient with Hodgkin’s disease of mixed cellularity subtype at primary diagnosis and in relapse two and a half years later. Ann Oncol 9:283–287PubMedCrossRefGoogle Scholar
  47. Jox A, Zander T, Küppers R et al. (1999) Somatic mutations within the untranslated regions of rearranged Ig genes in a case of classical Hodgkin’s disease as a potential cause for the absence of Ig in the lymphoma cells. Blood 93:3964–3972PubMedGoogle Scholar
  48. Jungnickel B, Staratschek-Jox A, Bräuninger A et al. (2000) Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin’s disease. J Exp Med 191:395–401PubMedCrossRefGoogle Scholar
  49. Kanzler H, Hansmann ML, Kapp U et al. (1996 a) Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin’s lymphoma patient. Blood 87:3429–3436PubMedGoogle Scholar
  50. Kanzler H, Küppers R, Hansmann ML, Rajewsky K (1996 b) Hodgkin and Reed-Sternberg cells in Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184:1495–1505PubMedCrossRefGoogle Scholar
  51. Kapp U, Yeh WC, Patterson B et al. (1999) Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 189:1939–1946PubMedCrossRefGoogle Scholar
  52. Kelly WD, Lamb DL, Vareo R, Good RA (1960) An investigation of Hodgkin’s disease with respect to the problem of homotransplantation. Ann NY Acad Sci 87:187–202PubMedCrossRefGoogle Scholar
  53. Kibbelaar RE, Kamp H van, Dreef EJ et al. (1992) Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood 79:1823–1828PubMedGoogle Scholar
  54. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N (1998) Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 95:11963–11968PubMedCrossRefGoogle Scholar
  55. Küppers R, Rajewsky K, Zhao M et al. (1994) Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 91:10962–10966PubMedCrossRefGoogle Scholar
  56. Liu YJ, de Bouteiller O, Fugier-Vivier I (1997) Mechanisms of selection and differentiation in germinal centers. Curr Opin Immunol 9:256–262PubMedCrossRefGoogle Scholar
  57. Longo DL (1990) The use of chemotherapy in the treatment of Hodgkin’s disease. Semin Oncol 17:716–735PubMedGoogle Scholar
  58. Longo DL, Duffey PL, Young RC et al. (1992) Conventionaldose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10:210–218PubMedGoogle Scholar
  59. Mack TM, Cozen W, Shibata DK et al. (1995) Concordance for Hodgkin’s disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med 332:413–418PubMedCrossRefGoogle Scholar
  60. Marafioti T, Hummel M, Anagnostopoulos I et al. (1997) Origin of nodular lymphocyte-predominant Hodgkin’s disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 337:453–458PubMedCrossRefGoogle Scholar
  61. Marafioti T, Hummel M, Anagnostopoulos I, Foss HD, Huhn D, Stein H (1999) Classical Hodgkin’s disease and follicular lymphoma originating from the same germinal center B cell. J Clin Oncol 17:3804–3809PubMedGoogle Scholar
  62. Marafioti T, Hummel M, Foss H-D et al. (2000) Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 95:1443–1450PubMedGoogle Scholar
  63. Mauch P, Larson D, Osteen R et al. (1990) Prognostic factors for positive surgical staging in patients with Hodgkin’s disease. J Clin Oncol 8:257–265PubMedGoogle Scholar
  64. Montesinos-Rongen M, Roers A, Küppers R, Rajewsky K, Hansmann M-L (1999) Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin’s disease. Blood 94:1755–1760PubMedGoogle Scholar
  65. Müschen M, Rajewsky K, Bräuninger A et al. (2000 a) Rare occurrence of classical Hodgkin’s disease as a T cell lymphoma. J Exp Med 191:387–394PubMedCrossRefGoogle Scholar
  66. Müschen M, Re D, Bräuninger A et al. (2000 b) Somatic mutations of the CD95 gene in Hodgkin and Rud-Sternberg cells. Cancer Res 60:5640–5643PubMedGoogle Scholar
  67. Ohno T, Stribley JA, Wu G, Hinrichs SH, Weisenburger DD, Chan WC (1997) Clonality in nodular lymphocyte-predominant Hodgkin’s disease. N Engl J Med 337:459–465PubMedCrossRefGoogle Scholar
  68. Oza AM, Tonks S, Lim J, Fleetwood MA, Lister TA, Bodmer JG (1994) A clinical and epidemiological study of human leukocyte antigen-DPB alleles in Hodgkin’s disease. Cancer Res 54:5101–5105PubMedGoogle Scholar
  69. Pavlovsky S, Maschio M, Santarelli MT et al. (1988) Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin’s disease. J Natl Cancer Inst 80:1466–1473PubMedCrossRefGoogle Scholar
  70. Poppema S (1996) Immunology of Hodgkin’s disease. Baillieres Clin Haematol 9:447–457PubMedCrossRefGoogle Scholar
  71. Poppema S, Potters M, Emmens R, Visser L, Berg A van den (1999) Immune reactions in classical Hodgkin’s disease. Semin Hematol 36:253–259PubMedGoogle Scholar
  72. Rajewsky K (1996) Clonal selection and learning in the antibody system. Nature 381:751–758PubMedCrossRefGoogle Scholar
  73. Re D, Hofmann A, Wolf J, Diehl V, Staratschek-Jox A (2000) Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95. Exp Hematol 28:31–35PubMedCrossRefGoogle Scholar
  74. Reed D (1902) On the pathological changes in Hodgkin’s disease with special reference to its relation to tuberculosis. John Hopkins Hosp Rep 10:133–193Google Scholar
  75. Ricci M, Romagnani S (1980) Immune status in Hodgkin’s disease. In: Doria G, Eskol A (eds) The immune system: function and therapy of dysfunction. Academic Press, New York, pp 105–130Google Scholar
  76. Romagnani S, Del Prete GF, Maggi E et al. (1983) Displacement of T lymphocytes with the ‘helper/inducer’ phenotype from peripheral blood to lymphoid organs in untreated patients with Hodgkin’s disease. Scand J Haematol 31:305–314PubMedCrossRefGoogle Scholar
  77. Roskrow MA, Suzuki N, Gan Y et al. (1998) Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin’s disease. Blood 91:2925–2934PubMedGoogle Scholar
  78. Roth J, Daus H, Trümper L, Gause A, Salamon-Looijen M, Pfreundschuh M (1994) Detection of immunoglobulin heavy-chain gene rearrangement at the single-cell level in malignant lymphomas: no rearrangement is found in Hodgkin and Reed-Sternberg cells. Int J Cancer 57:799–804PubMedCrossRefGoogle Scholar
  79. Schlegelberger B, Weber-Matthiesen K, Himmler A et al. (1994) Cytogenetic findings and results of combined immunophenotyping and karyotyping in Hodgkin’s disease. Leukemia 8:72–80PubMedGoogle Scholar
  80. Schmitz N, Sextro M, Hasenclever D (1997) HD-R1: first results of a randomized trial comparing aggressive chemotherapy with high-dose therapy (HDT) and hematopoietic stem cell transplantation (HSCT) in first patients with chemo-sensitive relapse of Hodgkin’s disease (HD). Blood [Suppl 1] 10:115aGoogle Scholar
  81. Schouten HC, Sanger WG, Duggan M, Weisenburger DD, MacLennan KA, Armitage JO (1989) Chromosomal abnormalities in Hodgkirís disease. Blood 73:2149–2154PubMedGoogle Scholar
  82. Seitz V, Hummel M, Marafioti T, Anagnostopoulos I, Assaf C, Stein H (2000) Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 95:3020–3024PubMedGoogle Scholar
  83. Staratschek-Jox A, Kotkowski S, Belge G et al. (2000) Detection of Epstein-Barr virus in Hodgkin-Reed-Sternberg cells. No evidence for the persistence of integrated viral fragments in latent membrane protein-1 (LMP-1)-negative classical Hodgkin’s disease. Am J Pathol 156:209–216PubMedCrossRefGoogle Scholar
  84. Sternberg C (1898) Über eine eigenartige unter dem Bilde der Pseudoleukämie verlaufende Tuberkulose des lymphatischen Apparates. Z Heilkd 19:21–90Google Scholar
  85. Teruya-Feldstein J, Jaffe E, Burd PR, Kingma DW, Setsuda JE, Tosato G (1999) Differential chemokine expression in tissues involved by Hodgkin’s disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood 93:2463–2470PubMedGoogle Scholar
  86. Thangavelu M, Le Beau MM (1989) Chromosomal abnormalities in Hodgkin’s disease. Hematol Oncol Clin North Am 3:221–236PubMedGoogle Scholar
  87. Tilly H, Bastard C, Delastre T et al. (1991) Cytogenetic studies in untreated Hodgkin’s disease. Blood 77:1298–1304PubMedGoogle Scholar
  88. Trümper LH, Brady G, Bagg A et al. (1993) Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood 81:3097–3115PubMedGoogle Scholar
  89. Trümper L, Pfreundschuh M, Jacobs G et al. (1996) N-ras genes are not mutated in Hodgkin and Reed-Sternberg cells: results from single cell polymerase chain-reaction examinations. Leukemia 10:727–730PubMedGoogle Scholar
  90. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA (1988) Risk of second cancers after treatment for Hodgkin’s disease. N Engl J Med 318:76–81PubMedCrossRefGoogle Scholar
  91. Van den Berg A, Visser L, Poppema S (1999) High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltration Hodgkin’s lymphoma. Am J Pathol 154:1685–1691PubMedCrossRefGoogle Scholar
  92. Vockerodt M, Soares M, Kanzler H et al. (1998) Detection of clonal Hodgkin and Reed-Sternberg cells with identical somatically mutated and rearranged VH genes in different biopsies in relapsed Hodgkin’s disease. Blood 92:2899–2907PubMedGoogle Scholar
  93. Wagner SD, Neuberger MS (1996) Somatic hypermutation of immunoglobulin genes. Annu Rev Immunol 14:441–457PubMedCrossRefGoogle Scholar
  94. Weber-Matthiesen K, Deerberg J, Poetsch M, Grote W, Schlegelberger B (1995) Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin’s disease. Blood 86:1464–1468PubMedGoogle Scholar
  95. Weiss LM, Chan JKC, MacLennan K, Warnke RA (1999) Pathology of classical Hodgkin’s disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM (eds) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, pp 101–120Google Scholar
  96. Wilson JB, Bell JL, Levine AJ (1996) Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 15:3117–3126PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Ralf Küppers
  • Klaus Rajewsky
  • Andrea Staratschek-Jox
  • Jürgen Wolf
  • Volker Diehl

There are no affiliations available

Personalised recommendations